scholarly journals Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli.

1985 ◽  
Vol 27 (2) ◽  
pp. 246-251 ◽  
Author(s):  
J R Rodriguez ◽  
C H Ramirez-Ronda ◽  
M Nevarez
Keyword(s):  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Efficacy And Safety ◽  
Lower Respiratory Tract Infections ◽  
Gram Negative ◽  
Tract Infections

scholarly journals Ritkábban előforduló, alsó légúti fertőzést okozó Gram-negatív nem fermentáló pálcák

2018 ◽  
Vol 159 (1) ◽  
pp. 23-30
Author(s):  
Emese Juhász ◽  
Miklós Iván ◽  
Júlia Pongrácz ◽  
Katalin Kristóf
Keyword(s):  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Diffusion Method ◽  
Lower Respiratory Tract Infections ◽  
Gram Negative ◽  
Maldi Tof Ms ◽  
Maldi Tof ◽  
Tract Infections ◽  
Tof Ms

Abstract: Introduction: Glucose non-fermenting Gram-negative bacteria are ubiquitous environmental organisms. Most of them are identified as opportunistic, nosocomial pathogens in patients. Uncommon species are identified accurately, mainly due to the introduction of matrix-assisted laser desorption-ionization time of flight mass spectrometry (MALDI-TOF MS) in clinical microbiology practice. Most of these uncommon non-fermenting rods are isolated from lower respiratory tract samples. Their significance in lower respiratory tract infections, such as rules of their testing are not clarified yet. Aim: The aim of this study was to review the clinical microbiological features of these bacteria, especially their roles in lower respiratory tract infections and antibiotic treatment options. Method: Lower respiratory tract samples of 3589 patients collected in a four-year period (2013–2016) were analyzed retrospectively at Semmelweis University (Budapest, Hungary). Identification of bacteria was performed by MALDI-TOF MS, the antibiotic susceptibility was tested by disk diffusion method. Results: Stenotrophomonas maltophilia was revealed to be the second, whereas Acinetobacter baumannii the third most common non-fermenting rod in lower respiratory tract samples, behind the most common Pseudomonas aeruginosa. The total number of uncommon non-fermenting Gram-negative isolates was 742. Twenty-three percent of isolates were Achromobacter xylosoxidans. Beside Chryseobacterium, Rhizobium, Delftia, Elizabethkingia, Ralstonia and Ochrobactrum species, and few other uncommon species were identified among our isolates. The accurate identification of this species is obligatory, while most of them show intrinsic resistance to aminoglycosides. Resistance to ceftazidime, cefepime, piperacillin-tazobactam and carbapenems was frequently observed also. Conclusions: Ciprofloxacin, levofloxacin and trimethoprim-sulfamethoxazole were found to be the most effective antibiotic agents. Orv Hetil. 2018; 159(1): 23–30.

Clinical efficacy and safety of silver nanoparticlebased disinfectant combined with piperacillin sodium and sulbactam sodium in the treatment of lower respiratory tract infection

2020 ◽  
Vol 10 (5) ◽  
pp. 756-761
Author(s):  
Xiaofei Li ◽  
Lina Sheng ◽  
Juncai Tu ◽  
Lianqing Lou
Keyword(s):  
Tract Infection ◽  
Respiratory Tract ◽  
Silver Nanoparticle ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Control Group ◽  
Efficacy And Safety ◽  
Lower Respiratory Tract Infections ◽  
Tract Infections ◽  
Experimental Group

This study evaluated the clinical efficacy and safety of piperacillin sulbactam in the treatment of lower respiratory tract infections, as well as the efficacy of silver nanoparticle-based disinfectant in equipment disinfection to reduce exogenous infection. From May 2018 to November 2018, 100 patients that had been diagnosed with a lower respiratory tract infection and hospitalized were divided into an experimental group and a control group. The experimental group was given piperacillin/sulbactam, and the control group was given mezlocillin/sulbactam, where 5.0 g was added to 100 mL of normal saline and administered via intravenous drip twice a day over a treatment course of 14 days. The cure rate of the experimental and control groups were 65.22% and 56.52% respectively. The efficacy rate was 91.30% and 91.30% respectively, with no significant difference between the two groups (P > 0.05). The results indicated that piperacillin/sulbactam is a safe, effective treatment for lower respiratory tract infections in elderly patients, the equipment was sterilized with silver nanoparticle-based disinfectant to reduce the incidence of adverse reactions and exogenous infections.

scholarly journals Pneumonia in Cats associated with Neisseria sp.

2021 ◽  
Vol 71 (2) ◽  
pp. 211-218
Author(s):  
Herica Makino ◽  
Alessandra Tammy Hayakawa Ito De Sousa ◽  
Lucas Avelino Dandolini Pavelegini ◽  
Yolanda Paim Arruda Trevisan ◽  
Edson Moleta Colodel ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Molecular Diagnosis ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Correct Identification ◽  
Lower Respiratory Tract Infections ◽  
Gram Negative ◽  
Mucosal Surfaces ◽  
Tract Infections ◽  
Veterinary Hospital

Abstract Neisseria sp. is a Gram-negative diplococcus bacterium usually present on the mucosal surfaces of animals without causing an obvious pathology. The objective of this study was to report the isolation of Neisseria sp. from severe cases of pyogranulomatous pneumonia with the formation of a Splendore-Hoeppli structure in two cats treated at a veterinary hospital. This paper suggests that the Neisseria genus members may be involved in lower respiratory tract infections in cats, with the molecular diagnosis being a necessary method for the correct identification of this bacteria in animals.

scholarly journals 1587. Activity of Ceftolozane/Tazobactam against Gram-Negative Isolates from Lower Respiratory Tract Infections – SMART United States 2018

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S790-S791
Author(s):  
Sibylle Lob ◽  
Meredith Hackel ◽  
Daryl DePestel ◽  
Katherine Young ◽  
Mary Motyl ◽  
...  
Keyword(s):  
United States ◽  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
The United States ◽  
Lower Respiratory Tract Infections ◽  
Independent Contractor ◽  
Gram Negative ◽  
The Us ◽  
Tract Infections

Abstract Background Ceftolozane/tazobactam (C/T) is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor. C/T has been approved by the FDA and EMA for complicated urinary tract infections, complicated intraabdominal infections, and hospital-acquired and ventilator-associated bacterial pneumonia. Using isolates collected in the United States as part of the global SMART surveillance program, we evaluated the activity of C/T and comparators against gram-negative pathogens collected from patients with lower respiratory tract infections (LRTI). Methods In 2018, 24 hospitals in the US each collected up to 100 consecutive aerobic or facultative gram-negative bacilli (GNB) from LRTI for a total of 1773 isolates. MICs were determined using CLSI broth microdilution and breakpoints. C/T-nonsusceptible (NS) Enterobacterales and P. aeruginosa isolates were screened by PCR and sequencing for genes encoding β-lactamases. Results The 3 most common species collected from LRTI were P. aeruginosa (35.0% of all collected GNB), K. pneumoniae (10.4%), and E. coli (9.6%). Enterobacterales and P. aeruginosa combined comprised 86.3% of all collected LRTI GNB. The activity of C/T and comparators against GNB from LRTI is shown in the table. C/T was active against 93% of Enterobacterales isolates from LRTI (activity only exceeded by meropenem and amikacin), as well as against 97% of P. aeruginosa and 94% of all Enterobacterales and P. aeruginosa combined (activity only exceeded by amikacin). C/T maintained activity against 69-83% of β-lactam-NS subsets of Enterobacterales and P. aeruginosa combined. Among 67 molecularly characterized C/T-NS Enterobacterales isolates, 19.4% carried KPC, 1.5% acquired AmpC, and 16.4% only extended-spectrum β-lactamases. No acquired β-lactamases were detected in the remaining 62.7% of isolates, of which 92.9% were species with intrinsic AmpC. Among 21 molecularly characterized C/T-NS P. aeruginosa, one isolate carried an IMP-type metallo-β-lactamase, and in the remaining isolates no acquired β-lactamases were detected. Table Conclusion With its broad coverage of Enterobacterales and P. aeruginosa, C/T can provide an important empiric therapy option for patients with LRTI in the US. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Daryl DePestel, PharmD, BCPS-ID, Merck & Co, Inc (Employee) Katherine Young, MS, Merck & Co., Inc. (Employee, Shareholder)Merck & Co., Inc. (Employee, Shareholder) Mary Motyl, PhD, Merck & Co, Inc (Employee, Shareholder) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)

Sign in / Sign up

Export Citation Format

Share Document